The new facility will produce medicines focused in the areas of oncology, covering both cancer and blood disorders
Sandoz Technical Operations, a Novartis division, inaugurated its manufacturing plant for medicines and therapies at Kalwe in Mumbai. The plant, which marks a new chapter for Sandoz, will further strengthen the company’s operations in India to support growing healthcare needs globally. The new facility will manufacture oral cancer medicines for the global market and will play a key role in enabling the delivery of high-quality cancer treatment.
Spread across 32000 sq mt, and housing state-of-the-art production technology, the plant is built to cater to the export markets, with Olaparib tablets, Darolutamide tablets and Lenvatinib capsules being the top molecules to be manufactured here. The plant currently has a workforce of 70 people with plans to recruit 200 more employees to support the expansion of the production capacity, capability, and development. Additionally, built on a brownfield, effluent treatment units installed at the plant shape a next-gen environmentally sustainable manufacturing atmosphere.
Commenting on the inauguration of the plant, Sanjay Murdeshwar, Country President, Novartis India said, “Today is an important milestone for us at Sandoz. The inauguration of the new production and launch site for oncology oral solids at Kalwe in India is a step forward in our constant endeavour to meet the growing demand for generic oral anti-cancer agents across the world and reinforces our position as an industry leader. Moreover, the launch of this facility deepens our commitment to supporting the government’s ‘Make in India’ vision to solve the evolving needs of patients across the world.”
With a relentless focus on patients at Sandoz, the commitment to deliver breakthrough innovation that changes the standard of care for patients across the world remains.
